Talia Golan

19.3k citations

170 papers · 7.2k indexed · 4 hit papers · h-index 39

Impact in

Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics

Papers in

Oncology 137
- Pancreatic and Hepatic Oncology Research 73
- PARP inhibition in cancer therapy 35
- Cancer Immunotherapy and Biomarkers 30
- Colorectal Cancer Treatments and Studies 20
Cancer Research 54
- Cancer Genomics and Diagnostics 46

Co-authors: Eileen M. O’Reilly Hedy L. Kindler Gershon Y. Locker Pascal Hammel Daniel Hochhauser Michele Reni Teresa Macarulla Eric Van Cutsem
Journals: Journal of Clinical Oncology (53 papers)Annals of Oncology (21 papers)European Journal of Cancer (6 papers)Cancer Research (4 papers)International Journal of Radiation Oncology*Biology*Physics (4 papers)
Partner nations: Israel United States South Korea

In The Last Decade

Talia Golan

161 papers receiving 7.1k citations

Hit Papers

align trajectories log scale

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 · 190 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Annals of Oncology
2021 Annals of Oncology
2019 New England Journal of Medicine
2016 The Lancet Oncology

Peers

Countries citing papers authored by Talia Golan

Since Specialization

Citations

This map shows the geographic impact of Talia Golan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talia Golan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talia Golan more than expected).

Fields of papers citing papers by Talia Golan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Talia Golan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talia Golan. The network helps show where Talia Golan may publish in the future.

Co-authors

The 25 scholars most cited alongside Talia Golan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Talia Golan Line = papers co-authored together Talia Golan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas Clinical Cancer Research ·Kevin J. Harrington, Stéphane Champiat, Joshua Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John Hyngstrom, James Strauss, David Y. Oh, Aron Popovtzer, Carlos Gomez‐Roca, Ruth Perets, Sung‐Bae Kim, Deborah J. Wong, Steven Powell, Anuradha Khilnani, Thomas Jemielita, Qing Zhao, Runchen Zhao, Matthew Ingham	2025	10
2	Multi-institutional validation survey on Belong.life's conversational artificial intelligence (AI) oncology mentor, "Dave. Journal of Clinical Oncology ·Talia Golan, Ofer Purim, Danny Rosin, Eli Sapir, Moshe E. Gatt, Tomer Charas, Ilya Iofin, Ido Wolf, Bozhena Haikin, Daniel Vorobiof	2024	1
3	Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications. Journal of Clinical Oncology ·Ruth Perets, Manish Sharma, John H. Strickler, Talia Golan, Antoine Hollebecque, William R. Henner, Athanasios Vasilopoulos, Gladys Morrison Thiele, Michael Charles Burns, James J. Harding	2024	0
4	Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer Oncology and Therapy ·Naama Halpern, Ben Boursi, Einat Shacham‐Shmueli, Einav Nili Gal‐Yam, Ofer Margalit, Talia Golan, Tamar Beller, Gal Strauss, Dafna Yahav, Eyal Leshem	2023	0
5	161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors Immuno-Oncology Technology ·Ruth Perets, Salomon M. Stemmer, Ravit Geva, Talia Golan, Marwan Fakih, Justine V. Cohen, Christopher H. Lieu, Zhaohui Jin, P. Lorusso, Natalia Ashtamker, I. Friedman, Motti Hakim, N. Crawford, Raymond P. Perez, Mansi Agarwal, Giovanni Abbadessa, Ming‐Shiang Wu, Yi-Chan Lin, Cecilia Deantonio, Mitesh J. Borad	2023	1
6	Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology ·Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, Ángela Lamarca, Thomas Seufferlein, Eileen M. O’Reilly, Thilo Hackert, Talia Golan, Gerald W. Prager, Karin Haustermans, Arndt Vogel, Michel Ducreux Hit paper breakdown →	2023	190
7	Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer Cancer ·Hedy L. Kindler, Hyun Kyoo Yoo, Robert Hettle, Karen Cui, Seongjung Joo, Gershon Y. Locker, Talia Golan	2023	8
8	POLQ inhibition elicits an immune response in homologous recombination–deficient pancreatic adenocarcinoma via cGAS/STING signaling Journal of Clinical Investigation ·Grace E. Oh, Annie Wang, Lidong Wang, Jiufeng Li, Gregor Werba, Daniel Weissinger, Ende Zhao, Surajit Dhara, Rosmel E. Hernandez, Amanda Ackermann, Sarina Y. Porcella, Despoina Kalfakakou, Igor Dolgalev, Emily Kawaler, Talia Golan, Theodore H. Welling, Agnel Sfeir, Diane M. Simeone	2023	39
9	RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer Nature ·Amina Jbara, Kuan‐Ting Lin, Chani Stossel, Zahava Siegfried, Haya Shqerat, Adi Amar-Schwartz, Ela Elyada, Maxim Mogilevsky, Maria Raitses‐Gurevich, Jared L. Johnson, Tomer M. Yaron, Ofek Ovadia, Gun Ho Jang, Miri Danan-Gotthold, Lewis C. Cantley, Erez Y. Levanon, Steven Gallinger, Adrian R. Krainer, Talia Golan, Rotem Karni	2023	55
10	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer Journal of Clinical Oncology ·Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan	2022	120
11	Loss of tumor suppressor WWOX accelerates pancreatic cancer development through promotion of TGFβ/BMP2 signaling Cell Death and Disease ·Hussam Husanie, Muhannad Abu‐Remaileh, Kian Maroun, L. Abu-Tair, Hazem Safadi, Karine Atlan, Talia Golan, Rami I. Aqeilan	2022	9
12	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition Molecular Cancer Research ·Alex Haber, Aditi Jain, Chinnadurai Mani, Avinoam Nevler, Lebaron C. Agostini, Talia Golan, Komaraiah Palle, Charles J. Yeo, William H. Gmeiner, Jonathan R. Brody	2021	16
13	Patient-derived xenograft models of BRCA-associated pancreatic cancers Advanced Drug Delivery Reviews ·Talia Golan, Dikla Atias, Chani Stossel, Maria Raitses‐Gurevich	2021	10
14	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors Clinical Cancer Research ·Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen, Richard Wnek, Georgina V. Long	2020	46
15	Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) European Journal of Cancer ·Yung‐Jue Bang, Talia Golan, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Keunchil Park, Ravit Geva, Filippo de Braud, Zev A. Wainberg, Martin Reck, Laura W. Goff, Naomi Laing, Gu Mi, Joana Oliveira, Heather Wasserstrom, Chia‐Chi Lin	2020	103
16	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition Molecular Cancer Research ·Teena Dhir, Christopher W. Schultz, Aditi Jain, Samantha Z. Brown, Alex Haber, Austin Goetz, Chunhua Xi, Gloria H. Su, Liang Xu, James Posey, Wei Jiang, Charles J. Yeo, Talia Golan, Michael J. Pishvaian, Jonathan R. Brody	2019	44
17	Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer New England Journal of Medicine ·Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler Hit paper breakdown →	2019	1468
18	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib Annals of Oncology ·P. Hammel, Hedy L. Kindler, Michele Reni, Eric Van Cutsem, Teresa Macarulla, C. Michael Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, S. Joo, Hyun Kyoo Yoo, Nikunj Patel, Talia Golan	2019	33
19	Abstract CT147: Celiac plexus radiosurgery a new palliative modality for upper gastrointestinal malignancies - final quality of life results from a proof-of-concept clinical trial Cancer Research ·Yaacov Richard Lawrence, Liat Hammer, Ofir Morag, Maoz Ben-Ailan, D. Alezra, Ofer Margalit, Naama Halpern, Ben Boursi, Einat Shmueli, Galia Jacobson, Uri Amit, Tamar Katzman, Kinneret Shefer, Ilana Weiss, Inessa Yanovsky, Adam P. Dicker, Talia Golan, Zvi Symon, David Hausner	2019	1
20	Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer Nature Communications ·Hadas Gibori, Shay Eliyahu, Adva Krivitsky, Dikla Ben‐Shushan, Yana Epshtein, Galia Tiram, Rachel Blau, Paula Ofek, Joo Sang Lee, Eytan Ruppin, Limor Landsman, Iris Barshack, Talia Golan, Emmanuelle Merquiol, Galia Blum, Ronit Satchi‐Fainaro	2017	79

About Talia Golan

Talia Golan is a scholar working on Oncology, Cancer Research, Anesthesiology and Pain Medicine, Pulmonary and Respiratory Medicine and Biotechnology, having authored 170 papers that have together received 7.2k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (73 papers), Cancer Genomics and Diagnostics (46 papers), PARP inhibition in cancer therapy (35 papers), Cancer Immunotherapy and Biomarkers (30 papers), Colorectal Cancer Treatments and Studies (20 papers), BRCA gene mutations in cancer (16 papers), Gastric Cancer Management and Outcomes (15 papers) and Genetic factors in colorectal cancer (12 papers). The work is most often cited by research in Oncology (5.4k citations), Cancer Research (2.3k citations), Gastroenterology (316 citations), Pulmonary and Respiratory Medicine (1.7k citations) and Immunology (1.1k citations). Talia Golan has collaborated with scholars based in Israel, United States and South Korea. Frequent co-authors include Eileen M. O’Reilly, Hedy L. Kindler, Gershon Y. Locker, Pascal Hammel, Daniel Hochhauser, Michele Reni, Teresa Macarulla, Eric Van Cutsem, Michael J. Hall and Ravit Geva. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact